Thiogenesis hires Brisco Capital for investor relations
Thiogenesis Therapeutics said it has engaged Brisco Capital for investor relations. The company is a clinical-stage biotech developing sulfur-based therapeutics for rare diseases.
San Diego, California--(. - September 3, 2026) - Thiogenesis Therapeutics, Corp.
TSXV:TTI (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital P…